BCL2L1 and colorectal cancer: Collectively, these data indicate that concomitant suppression of the antiapoptotic protein Bcl-xL, thereby “freeing” BIM, is needed for a robust apoptotic response after KRASG12C inhibition in KRASG12CMT colorectal cancer.